Overview
- The proposal outlines a route to approve bespoke treatments for ultra‑rare, hard‑to‑study genetic diseases when randomized trials are not feasible.
- It centers on genome‑editing and RNA‑based therapies and may extend to other targeted products under defined criteria.
- Sponsors could seek approval using small, well‑controlled studies that show early efficacy signals supported by strong biological rationale.
- Post‑approval obligations include real‑world evidence and confirmatory studies, with the FDA warning it can withdraw products that fail to verify benefit, while manufacturing standards remain unchanged.
- The pathway creates a standardized process that can enable commercialization beyond compassionate use, and FDA officials anticipate a surge of applications following the draft’s release.